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ABSTRACT – Purpose. ATPases, which constitute a major category of ion transporters in the human body, 
have a variety of significant biological and pathological roles. However, the lack of high throughput assays 
for ATPases has significantly limited drug discovery in this area. We have recently found that the genetic 
deletion of the ATP dependent calcium pump PMCA4 (plasma membrane calcium/calmodulin dependent 
ATPase, isoform 4) results in infertility in male mice due to a selective defect in sperm motility. In addition, 
recent discoveries in humans have indicated that a single nucleotide polymorphism (SNP) in the PMCA4 
gene determines the susceptibility towards malaria plasmodium infection. Therefore, there is an urgent need 
to develop specific PMCA4 inhibitors. In the current study, we aim to optimise and validate a high 
throughput screening compatible assay using recombinantly expressed PMCA4 and the HTRF® 
Transcreener® ADP (TR-FRET) assay to screen a drug library. Methods and Results. PMCA4 membrane 
microsomes were prepared from HEK293 cells overexpressing PMCA4. Western blot quantification 
revealed nearly nine-fold increased expression of PMCA4 compared to LacZ (control virus)-infected cells. 
Maximal PMCA4 microsomal activity was achieved in the TR-FRET assay with 15ng/μl microsomal 
concentration, 30-minute pre-incubation with compounds at 37°C, and calcium buffering with 1mM EGTA 
providing 1μM free-calcium. Finally a dose-response curve for carboxyeosin (a non-specific PMCA 
inhibitor) under optimised conditions showed significant PMCA4 inhibition. Upon confirmation that the 
assay was suitable for high-throughput screening, we have screened the ChemBioNet small molecule library 
(~21,000 compounds) against the PMCA4 assay to identify those that are its apparent inhibitors. This 
screening yielded 1,494 primary hits. Conclusions. We have optimised the HTRF® Transcreener® ADP 
assay for high-throughput screening to identify PMCA4 inhibitors. The output of the screening campaign 
has provided preliminary chemical starting points that could be further developed to specific PMCA4 
inhibitors for non-hormonal contraception or anti-malaria therapy. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
INTRODUCTION 
 
P-type ATPases are a group of protein which 
utilise the energy generated from adenosine 
triphosphate (ATP) hydrolysis predominantly to 
facilitate the movement of cations, Na+, K+, H+ or 
Ca2+ against the concentration gradient. In the 
human body, examples include the sodium-
potassium pump (Na+/K+-ATPase), the proton 
pump (H+/K+ ATPase), sarco-endoplasmic 
reticulum calcium ATPase (SERCA), and the 
plasma membrane calcium/calmodulin dependent 
ATPase (PMCA). The Na+/K+-ATPase pump, 
which is ubiquitously expressed, facilitates cell 
ionic gradients, ionic transport, and in both 
neurones and muscle cells it maintains cell resting 
potential by extruding three sodium ions from the 
cell in exchange for two potassium ions. The 
activity of this enzyme energizes such diverse 
functions as the maintenance of the membrane 
potential and the renal and intestinal handling of 
solutes [1-3]. The gastric H+/K+-ATPase exploits 
a very similar enzymatic mechanism to catalyze 
the exchange of intracellular protons for  
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extracellular potassium ions, thus generating the 
enormous proton gradients associated with gastric 
acid secretion [4]. SERCA is ubiquitously 
expressed, and is known to facilitate uptake of 
calcium into the sarco/endoplasmic reticulum 
from the cytosol. This is important in cardiac 
muscle relaxation, in which the sarcoplasmic 
reticulum is essentially refuelled with calcium for 
subsequent contraction to take place [5-9]. 
Finally, the PMCA family, are a group of pumps 
that extrude calcium from the cytosol into the 
extracellular space, control calcium homeostasis, 
and in some cases regulate intracellular signalling 
pathways. There are four main isoforms: PMCA1, 
2, 3 and 4, each one being encoded by a different 
gene. Every cell contains at least one PMCA 
isoform, with PMCA activity being driven by the 
hydrolysis of ATP [10, 11]. 
Recent Genome Wide Association Studies 
(GWAS) and studies of genetically modified mice 
have revealed potentially important roles for 
PMCA isoforms in human disease. A number of 
the human GWAS have identified single 
nucleotide polymorphisms (SNPs) in the PMCA1 
gene as the single strongest association with blood 
pressure (BP) variance in humans [12-15]. 
PMCA2 which is expressed in the cilia of the 
inner ear, Purkinje cells and the mammary gland, 
has been implicated in deafness [16-18]. PMCA3 
is expressed in brain tissue, pancreatic islet cells, 
and skeletal muscle, but less is known of the 
pathophysiological significance [19-21]. 
However, a recent study in humans has related a 
single mutation in PMCA3 with ataxia [22]. 
PMCA4 is by far the most extensively studied 
isoform. Our own studies in mice lacking PMCA4 
[23]  revealed that the males were infertile due to 
a defect in sperm motility, but were otherwise 
healthy under physiological conditions and had a 
normal lifespan, as did the females. These 
findings were confirmed by Okunade et al. who 
generated a similar PMCA4 knockout mouse 
model [24]. In addition, a GWAS has shown the 
PMCA4 gene to be associated with resistance to 
infection by malaria plasmodium in humans [25]. 
These findings have collectively implicated 
PMCAs in a variety of diseases and have led us to 
optimise and validate a generic PMCA screening 
compatible assay to be performed for drug 
discovery purposes. In the current study we used 
PMCA4 as a model to optimise and validate the 
HTRF® Transcreener® ADP (TR-FRET) assay for 
high throughput screening (HTS) of ATPase-
targeting compounds. This assay can also be 
applied to study other ATPases. 
METHODS 
 
Microsome preparation 
HEK293 cells overexpressing PMCA4 or β-
galctosidase (LacZ) were used to prepare PMCA4 
and LacZ microsomes as previously described 
[26]. Briefly, HEK293 cells were cultured and 
maintained in 175cm2 flasks, until cells were at 
60-70% confluence. Cells were then infected by 
25 Multiplicity Of Infection (MOI) with either 
recombinant PMCA4 or LacZ adenovirus, for 48 
hours. Cells were washed three times with PBS 
and then harvested in 5ml harvest solution (1x 
PBS, 0.26% 2mg/ml aprotinin, 0.11% 2mg/ml 
leupeptin, 0.1% 0.1M PMSF). Harvested cells 
were centrifuged at 1000g for 10 minutes at 4ºC. 
3ml hypotonic solution (10mM Tris-HCl, pH7.5, 
1mM MgCl2, 0.5mM EGTA, 2mM DTT, 0.2% 
2mg/ml aprotinin, and 0.05% 2mg/ml leupeptin) 
was added to the cell pellet for 10 minutes on ice. 
Swelled cells were homogenised in a Dounce 
homogenizer before addition of 3 ml homogenate 
solution (10mM Tris-HCl, pH7.5, 2mM DTT, 
0.38M sucrose, 0.3M KCl, 0.2% 2mg/ml 
aprotinin, and 0.05% 2mg/ml leupeptin) and 
homogenization was completed to seal the 
vesicles. The cell homogenate was centrifuged at 
1500g for 20 minutes to remove the cellular 
debris. 60µl 0.25mM EDTA and 1.08 ml of 2.5M 
KCl were added to the supernatant and 
centrifuged at 100,000g for 40 minutes at 4ºC. 
The resulting pellet was re-suspended in 0.4ml 
final solution (10mM Tris-HCl, pH7.5, 1mM 
DTT, 0.19M sucrose, 0.15M KCl, 0.2% 2mg/ml 
aprotinin, 0.05% 2mg/ml leupeptin and 0.02mM 
CaCl2).  
 
Western blotting 
Microsomes overexpressing PMCA4 or β-
galactosidase (LacZ) where lysed with RIPA 
buffer (1x PBS, 1% Igepal, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate 
[SDS], 20µM phenylmethylsulfonyl fluoride 
[PMSF], 500ng/ml leupeptin, 1.0µg/ml aprotinin, 
and 500ng/ml pepstatin). Protein concentrations 
were determined using a BCA protein assay kit 
(Pierce). 30µg of protein extracts were then 
separated by SDS-polyacrylamide gel 
electrophoresis and transferred on to a 
nitrocellulose membrane. Mouse monoclonal anti-
PMCA4 antibody [JA9] (Abcam) was used for the 
Western blot analysis and tubulin expression 
(Abcam) was used as a loading control. The levels 
of protein expression were quantified using 
ImageJ software (NIH).  
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Homogeneous Time Resolved Fluorescence 
(HTRF®) Transcreener® ADP assay 
The HTRF® Transcreener® ADP assay (Cisbio) 
was used as per manufacturer’s instructions with 
the following modifications. The assay was 
performed in low volume 384 well black 
microtitre plates in two steps, namely the 
enzymatic reaction step followed by a detection 
step. During the enzymatic reaction, 1µg of 
PMCA4 microsomes were incubated at 37ºC in a 
total volume of 10µl of the optimised reaction 
mixture containing 50mM Hepes-Tris pH 7.8, 
160mM KCl, 2mM MgCl2, 5mM NaN3, 1mM 
CaCl2, 1 mM EGTA, 1 unit calmodulin, 100µM 
ATP. For HTRF® Transcreener® ADP assay 
detection of ATP hydrolysis, 5µl of Eu3+-cryptate 
antibody and 5µl ADP-d2 solutions were added 
and the plate incubated at room temperature for 
60 minutes. The HTRF signal from each well was 
assessed using the FLUOstar Omega 
Multidetection Microplate Reader, with excitation 
filter at 337nm and using emission filters at 
680nm and 620nm for ADP-d2 and Eu3+-cryptate 
antibody respectively, the data analysis was 
performed using Omega software version 1.30 
(BMG Labtech). For all wells, F was calculated as 
the ratio between the 680nm reading and 620nm 
reading. The data were presented as ATPase 
activity (%) = (1- (dF/dFmax)) x 100. dF = ((FSample 
– FBlank) / (FBlank)) x 100 and dFmax = dF of 
inactive microsomes which fully inhibited with 
25mM EGTA. The TR-FRET ratio = signal665nm/ 
signal615nm = emmissiond2 acceptor dye/emissionEu3+-
cryptate. 
 
DATA AND STATISTICAL ANALYSIS 
 
Statistical tests were performed using SPSS. 
Following a Kolmogorov–Smirnov test normality 
test, groups were compared using the unpaired 
student T-test. P≤0.05 were considered to be 
statistically significant. 
RESULTS   
 
HTRF® Transcreener® ADP (TR-FRET) assay 
The HTRF® Transcreener® ADP (TR-FRET) 
assay (Cisbio) relies upon the hydrolysis of ATP 
to ADP. The detection method is based on an 
antibody specific to ADP which is labelled with 
Eu3+-cryptate,  which is also able to bind to either 
(d2 acceptor dye)-coupled-ADP (to produce a 
TR-FRET signal) or ADP released from the 
enzymatic ATPase reaction (no TR-FRET signal). 
The resulting TR-FRET signal is inversely 
proportional to the concentration of the non-
labelled ADP in the sample. As PMCA4 is an 
ATPase pump that has the ability to convert ATP 
to ADP with the release of inorganic phosphate 
(Pi) in a stoichiometric ratio, the released ADP 
due to ATP hydrolysis by PMCA4 would 
compete with ADP-d2 and reduce the TR-FRET 
signal (Figure. 1A). To ascertain that the HTRF 
assay is suitable to measure the ATPase activity, a 
standard curve was performed for different 
ATP:ADP ratios (Table 1). This dose response 
curve showed a constant increase in the 1- 
(dF/dFmax) values in response to increased 
ADP/ATP ratios until a plateau phase was 
reached (Figure. 1B). It was important to use 
different ADP/ATP ratios for the dose response 
curve to mimic the ATPase reaction (as ADP is 
produced, ATP is depleted). 
 
Generation of PMCA4 overexpressing 
microsomes  
PMCA4 microsomes were generated from the 
membranes of HEK293 cells infected with a 
PMCA4 adenovirus construct. Western blot 
analysis revealed ~10 times higher PMCA4 
protein expression in the PMCA4-infected cells 
compared to the LacZ-infected cells (P<0.001; 
n=5) (Figure. 2A, B).  
 
 
 
Table 1. ADP/ATP concentrations for standard curve: 
 ADP (µM) ATP (µM) ATP conversion (%) 
Standard 1 0 100 0 
Standard 2 0.14 99.86 0.14 
Standard 3 0.41 99.59 0.41 
Standard 4 1.23 98.77 1.23 
Standard 5 3.70 96.30 3.70 
Standard 6 11.11 88.89 11.11 
Standard 7 33.33 66.67 33.33 
Standard 8 100 0 100 
 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 16(2) 217 - 230, 2013 
 
 
 
 
220 
Optimisation of calcium buffering for the 
PMCA4 microsomes  
Since PMCA4 is a high affinity calcium pump it 
was important to determine the optimum 
concentration of freely available calcium ions for 
maximal PMCA4 microsomal activity, [11]. The 
calcium dependency of the activity of the PMCA4 
microsomal preparation was investigated in the 
presence of 0.1μM, 1μM, 10μM, 100μM, and 
1mM calcium chloride solution, as well as in the 
absence of external calcium chloride. The ATPase 
activity was consistently high (>80%, with a 
maximum around 90%) under all conditions with 
no inter-variability, suggesting oversaturation of 
PMCA4 microsomes with free calcium. Even 
when no calcium was added, the amount of 
calcium in the final solution where the 
microsomes were resuspended (20µM CaCl2) was 
sufficient to activate PMCA4 (Figure. 2C). 
By buffering calcium in the presence of 1mM 
EGTA, there was a complete inhibition of 
PMCA4 activity in all CaCl2 concentrations, 
except in the presence of 1mM CaCl2 where 
almost 100% ATPase activity in the PMCA4 
microsomes was observed (Figure. 2D). This 
suggests that 1mM EGTA does not fully chelate 
the calcium and sufficient calcium is available to 
activate PMCA4. Using an online software tool 
[27] based on the Fabiato formula [28], we 
calculated that 1mM EGTA in the presence of 
1mM CaCl2 would provide 4μM free calcium 
under these reaction conditions; which appear to 
be the optimal for PMCA4 activity to be 
maximized. At higher concentrations of EGTA 
(25mM), essentially all free calcium would be 
expected to be chelated and thus fully inhibit 
PMCA4 activity (Figure. 2E), which was 
confirmed by the fact that ≤30% ATPase activity 
was achieved across all CaCl2 concentrations. 
Finally, the inclusion of EDTA at 25mM 
indicated that ≤20% ATPase activity remained 
across all CaCl2 concentrations (Figure. 2F). 
Therefore, 4μM free calcium as achieved in the 
presence of 1mM EGTA and 1mM CaCl2 solution 
was verified as the optimum concentration to 
maximize PMCA4 activity and used in all the 
following experiments. 
 
Optimisation of the HTRF® Transcreener® 
ADP (TR-FRET) assay to screen for PMCA4 
inhibitors 
In order to determine the optimal conditions for 
the HTRF® Transcreener® ADP assay to screen 
for PMCA4 inhibitors, three further experiments 
were performed (Figures. 3A-C). First, PMCA4 
and LacZ (control) microsomes were tested at a 
range of different concentrations, up to 25ng 
(Figure. 3A). As expected, this experiment 
revealed minimal background ATPase activity 
with LacZ across all microsomal concentrations. 
These results were in contrast to the specific 
increasing ATPase activity with the PMCA4 
microsomes, which reached a plateau between 
10ng/µl and 15ng/µl. Therefore, 15ng/µl 
microsomes were used for subsequent 
experiments. In order to determine the optimum 
time period for incubation at 37°C of PMCA4 
microsomal preparations we tested the PMCA4 
microsomal activity at different time points, 10, 
30 and 60 minutes (Figure. 3B). The PMCA4 
activity was significantly higher and appeared to 
reach a plateau at both 30 and 60 minutes with no 
significant difference in PMCA4 activity between 
30 and 60 minutes (P=0.28, n=3) across all 
microsomal concentrations (10-25 ng/μl). 30 
minutes was therefore selected as the optimum 
timing for incubation at 37°C. In order to confirm 
that the measured PMCA4 activity could be 
inhibited, we used the optimised conditions 
(15ng/μl microsome preparation; 30 minutes of 
incubation period at 37°C), to test the effect of 
different concentrations of a known non-selective 
PMCA-inhibitor (carboxyeosin) [29-31] on 
PMCA4 activity (Figure. 3C). This curve showed 
a dose response correlation of PMCA4 ATPase 
activity inhibition by carboxyeosin with an IC50 of 
0.5µM, reaching almost zero PMCA4 activity at 
1μM carboxyeosin concentration. This finding 
verified that the HTRF® Transcreener® ADP 
assay has successfully been optimised to screen 
for PMCA4 inhibitors using the microsomal 
PMCA4 overexpression system. Furthermore, 
carboxyeosin was shown to be a suitable positive 
control inhibitor for use in a screening campaign. 
 
Automating the HTRF® Transcreener® ADP 
(TR-FRET) assay for high-throughput 
screening 
The feasibility of automating the assay using a 
robotic liquid handling system was assessed. The 
activity of the PMCA4 microsomes was 
determined in 384 well microtitre plates that were 
preloaded with 100nl DMSO in each well to 
determine if any edge effects and/or false 
positives were detected. Column 24 in each 
microtitre plate served as a negative control in 
which 1µM carboxyeosin was used to inhibit 
PMCA4. The signal was stable up to 4 hours with 
no significant variation between wells indicating 
low chances of producing false positives. In 
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addition, these results did not show edge effect 
that is usually apparent in assays that involve 
incubation at 37°C (Figure. 4A-C). Z' analysis 
was carried out to measure for the consistency of 
the readings across the positive and the negative 
control replicates in the plate (Z' = 1 - ((3 x 
(Standard Deviation of the Maximum Signal 
Control) + 3 x (Standard Deviation of the 
Minimum Signal Control))/((Mean of the 
Maximum Signal Control) – (Mean of the 
Minimum Signal Control))) [32]. The Z' analysis 
showed stability over different timing points 
which indicated the stability and consistency of 
the TR-FRET signal over time (Figure. 4D).     
 
Screening of ChemBioNet drug library to 
identify PMCA4 inhibitors 
To demonstrate that this assay can be used 
efficiently in a high throughput screening 
campaign, the PMCA4 assay was evaluated 
against the ChemBioNet small molecule library 
(~21,000 compounds) at a concentration of 
20µM. The TR-FRET assay allows the 
identification of optically interfering compounds 
by comparing the 620nm signal from the Eu3+-
cryptate channel in the presence of compounds 
with that of the DMSO control populations. 
Compounds with intensity in Eu3+-cryptate 
channel <70% and >130% of DMSO controls 
were classified as optical interfering compounds 
(quenching and auto-fluorescent respectively). 
This screening campaign revealed 1,494 apparent 
PMCA4 inhibitors when using a >50% inhibition 
cut-off after excluding the optical interfering 
compounds (Figure. 5).    
 
DISCUSSION 
 
The present study describes a HTRF® 
Transcreener® ADP (TR-FRET) assay that was 
successfully utilised in a high throughput 
screening campaign to identify PMCA4 
inhibitors. In addition this assay can be modified 
for other ATPases and it also offers the ability to 
identify ATPase stimulators. Although there are 
other ATPase assays that have been optimised for 
high throughput screening, these rely largely upon 
undesirable methods to detect ATPase activity 
[33-35]. Examples include use of radioactive 
scintillation proximity assay [33] or colorimetric 
assays [35], as well as coupled-enzyme systems 
[34] that detect phosphate production linked 
stoichiometrically to ATP hydrolysis. These 
assays depend on the hydrolysis of ATP to ADP 
and inorganic phosphate under the action of 
PMCA ATPase activity with the resulting 
inorganic phosphate forming a complex with the 
malachite green dye to produce a green colour 
which can be detected [36]. The colorimetric 
nature of these assays represents an obstacle for 
use in high or medium throughput screenings as 
coloured compounds might interfere with the 
results and produce false positive results. 
Moreover, compounds that either contain a free 
phosphate group or one that resembles it would be 
expected to yield false positive results. Therefore, 
our proposed TR-FRET assay is a robust and 
reliable ATPase assay that offers the ability to 
detect ADP release by ATPases using specific 
antibodies, thus more accurately and reliably 
measuring the rate of ATP hydrolysis. 
Furthermore, the flexibility of the fluorescent 
readings allows both inhibition and stimulation to 
be detected, enabling the assay to detect both 
inhibitors and stimulators of ATPase targets. In 
addition, our PMCA4 overexpression system 
using adenovirus resulted in ~10 fold 
overexpression of the PMCA4 protein which 
minimized the interference of the ecto-ATPases 
already expressed in the microsomes which was 
confirmed when comparing the PMCA4 
microsomes activity against LacZ microsomes. 
Using the current assay, it was possible to screen 
the ChemBioNet small molecule library for 
PMCA4-inhibitors in a single day, which 
contrasts with the enzyme-coupled assays that 
would not only take longer but would require 
suitable counter assays to identify those 
compounds that are acting upon the enzyme-
coupled system. The TR-FRET assay also allows 
the rapid identification of compounds that are 
either quenchers/autofluorescent which often 
appear as false positives in fluorescence based 
screening assays; these can be identified by 
comparing the signal at 620nm from the Eu3+-
cryptate channel with the DMSO controls. We 
chose a generous cut-off of <70% and >130% for 
classifying compounds as quenching and auto-
fluorescent respectively; which overcomes the 
need to perform additional counter assays [37]. 
This systematic approach led to fewer false-
positive hits and therefore a more reliable 
screening process.  
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Figure 1. Homogeneous time resolved fluorescence assay (HTRF) assay principle and standard curve: 
(A) Schematic diagram showing the assay principle for the HTRF® Transcreener® ADP assay (Cisbio). The detection 
method is based on an antibody specific to ADP which is labelled with Eu3+-cryptate,  which is also able to bind to 
either (d2 acceptor dye)-coupled-ADP (to produce TR-FRET) or ADP released from the enzymatic ATPase reaction 
(no TR-FRET . The resulting TR-FRET signal is inversely proportional to the concentration of the non-labelled ADP in 
the sample. As PMCA4 is an ATPase pump that has the ability to convert ATP to ADP with the release of inorganic 
phosphate in a stoichiometric ratio, the released ADP due to ATP hydrolysis by PMCA4 would compete with ADP-d2 
and reduce the TR-FRET signal. (B) Dose response for different ADP/ATP ratio which mimic an ATPase reaction (as 
ADP is produced, ATP is depleted).  
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Figure 2. PMCA4 expression in microsomal preparations and optimisation of calcium buffering:  
(A) Western blot analysis showing PMCA4 expression in PMCA4 microsomal membrane preparations against LacZ 
control microsomal preparations; α-tubulin was used as a loading control. (B) Quantification of PMCA4 
overexpression in PMCA4 and LacZ control microsomal preparations (n=6, *p<0.05). Assessment of PMCA4 
microsomes activity under various condition (n=3 independent experiments and each done in triplicate): (C) presence 
of different calcium concentrations; (D) after buffering calcium with 1mM EGTA; (E)  full calcium depletion with 
25mM EGTA ; (F) full calcium and magnesium depletion  with 25mM EDTA. For all assays, ATPase activity (%)  = 
(1- (dF/dFmax))x100. dF = (FSample – FBlank) / (FBlank) x 100 and dFmax = dF of inactive microsomes which fully inhibited 
with 25mM EGTA.  
J Pharm Pharmaceut Sci (www.cspsCanada.org) 16(2) 217 - 230, 2013 
 
 
 
 
224 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Optimisation of the assay conditions:  
(A) Dose response curve for PMCA4 and LacZ control microsomes shows the activity of PMCA4 microsomes 
increased by increasing the amount of microsomes until reaching the maximal activity from 10ng/ul.  However there is 
no considerable activity observed from the LacZ control microsomes (n=3). (B) Assessment of various incubation 
times on PMCA4 micosomal preparations shows that the maximal activity was reached after 30 minutes incubation 
(n=3, *p<0.05 vs 10 minutes). (C) Dose response curve for carboxyeosin (known PMCA non specific inhibitor)  using 
the optimised conditions of microsomal amount (15ng) and incubation time (30 minutes) (n=3, *p<0.05 vs no 
inhibitor). 
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Figure 4. Signal stability and Z':  
Using the optimised conditions of microsome concentration and incubation times, DMSO plates were tested to check 
for edge effect, false positives and signal stability for 1 (A), 2 (B) and 4 (C) hours. Columns 1-23 contains 15ng 
microsomes and column 24 served as a negative control in which 1µM carboxyeosin was used to inhibit PMCA4. (D) 
Z' index for the reproducibility of the signal after 1, 2 and 4 hours.   
 
 
The discovery of specific pharmacological 
inhibitors/stimulators for PMCA isoforms, 
SERCA2 and other ATPases is now becoming 
more important due to their relevance in several 
human diseases as suggested by recent GWAS 
and several animal studies. Our studies in mice 
lacking PMCA4 [23] have also found male mice 
to be infertile due to a defect in sperm motility. In 
addition a more recent GWAS showed that the 
PMCA4 gene was associated with resistance to 
infection by malaria plasmodium in humans [25].  
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Figure 5. The output of the screen for PMCA4 against the ChemBioNet small molecule library. 
Dot plot showing the inhibition (%) of the screened compounds. Compounds with intensity in the Eu3+-cryptate channel 
<70% and >130% of DMSO controls were classified and removed as optical interfering compounds. The blue coloured 
dots correspond to 1,494 compounds that were identified as apparent inhibitors (yielding >50% Inhibition) after 
excluding the optical interfering compounds.  
 
 
 
Therefore, the discovery of a specific inhibitor for 
PMCA4 could have further potential applications 
in the fields of contraception and anti-malaria 
treatment. In addition, several GWAS have 
indicated the PMCA1 gene as being strongest 
associated with blood pressure (BP) in humans 
[12-15], PMCA2 was found to be associated with 
deafness [16-18] and mutations in PMCA3 found 
to be associated ataxia [22]. There are additional 
ATPases that have been implicated in 
pathological remodelling during heart failure, in 
particular, evidence has suggested the benefits of 
upregulating SERCA to treat and prevent heart 
failure  [5, 7-9, 38, 39]. Subsequent to Gwathmey 
et al. [38] documenting abnormal calcium 
homeostasis in myocardial specimens of end-
stage heart failure patients compared with 
controls, Mercadier et al. [5] attributed this to a 
relative decrease in SERCA mRNA levels using 
similar tissue specimens and this has fueled 
interest in therapeutically upregulating SERCA 
expression to restore calcium handling and 
consequently improve cardiac 
contractility/relaxation. Therefore, the discovery 
of a small molecule stimulator to SERCA will 
potentially improve heart failure. 
It is currently estimated that the cost for 
successfully launching a new molecular entity is 
in the region of US $1,778 million [40]. This is 
due in part to the increasing scrutiny of the drug 
safety and efficacy by regulatory bodies including 
the Food and Drug Administration with 
pharmaceutical companies under greater pressure 
to perform more expensive comparative trials of 
J Pharm Pharmaceut Sci (www.cspsCanada.org) 16(2) 217 - 230, 2013 
 
 
 
 
228 
their new drugs against existing treatments [41]. 
Unsurprisingly, pharmaceutical companies are 
suffering a shortfall in profitability and 
productivity [40] which is exemplified by 
cardiovascular R&D that was adversely affected 
when Pfizer withdrew cardiovascular research 
funding in 2008 [42]. Recently, there has been 
more focus on bench-to-bedside approaches, with 
genomic studies unveiling more promising 
therapeutic targets for novel therapies [43] 
offering potential to ATPases that are implicated 
in various diseases. 
In summary, we have used PMCA4 as a 
model to optimise the HTRF® Transcreener® ADP 
assay for a high throughput screening campaign to 
identify ATPase inhibitors and stimulators. By 
generating microsomes that overexpress PMCA4, 
validating PMCA4 overexpression by Western 
blot, and determining the optimal conditions to 
maximize baseline PMCA4 ATPase activity, we 
have described a screening assay to identify 
effective inhibitors of PMCA4. Further research is 
underway to explore whether the PMCA4 
inhibitors exhibit suitable selectivity profiles with 
the ultimate aim to use them in animal models to 
assess their ability to treat malaria, or serve as a 
non-hormonal contraceptive. Utilising other 
mouse and human genome studies could also 
identify additional ATPase targets. Once such an 
ATPase target is identified, the HTRF® 
Transcreener® ADP assay (and associated 
microsomal system) can be used for high 
throughput screening of drug libraries to identify 
compounds for study in these additional disease 
indications, at least in suitable animal models. 
This translational research for discovering novel 
therapeutic targets is an essential step forward in 
drug development, and could potentially 
revolutionize pharmacological disease prevention 
and treatment. 
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